Anticarcinogenic Effects of Odorant Substances 
Citral, Citrathal R and Cyclovertal on Breast Cancer
in vitro

Anna-Lena Klauser,¹ Marc Hirschfeld,¹–³ Andrea Ritter,¹² Gerta Rücker,¹⁴ Markus Jäger,¹² Julia Gundarova,¹ Daniela Weiss,¹² Ingolf Juhasz-Boss,¹² Kai Ber ner,¹² Thalia Erbes,¹² Jasmin Asberger²

¹Faculty of Medicine, University of Freiburg, Freiburg, Germany; ²Department of Obstetrics and Gynecology, Medical Center – University of Freiburg, Freiburg, Germany; ³Institute of Veterinary Medicine, University of Göttingen, Göttingen, Germany; ⁴Institute of Medical Biometry and Statistics, Medical Center – University of Freiburg, Freiburg, Germany

Purpose: In 2020, breast cancer still represents the most common type of cancer in women worldwide. Depending on the specific molecular subtype, clinical breast cancer management comprises surgery, radiotherapy, chemotherapy and targeted therapy. Furthermore, there are some therapeutic approaches from the field of complementary and alternative medicine. Current research focuses on the elucidation of new therapeutic targets for treatment development. Odorant substances affect apoptosis, proliferation and cell cycle in healthy and cancerous cells. Exact signalling pathways involved are not entirely clear. The present study aims to analyse their therapeutic potential in breast cancer.

Methods: This study focuses on the effect of commonly used odorant substances (citral, citrathal R, cyclovertal, para-cymol, hexylacetat, herbavert, dihydromyrcanol and limonen) on the breast cancer cell lines MDA-MB-231, T47-D and BT474. Methodologically, this study applied cell culturing, MTT assay for detection of IC50 of the odorant substance, RNA purification followed by qRT-PCR, protein isolation and Western Blot, as well as immunocytochemistry. Further, this study investigates the role of transient receptor potential channel V1 (TRPV1), involved in the mechanisms of action for some odorant substances. Therefore, capsazepine, a TRPV1 antagonist, was used.

Results: The odorant substances citral, citrathal R and cyclovertal have significant pro-apoptotic (p < 0.001), anti-proliferative (p < 0.001) and cell cycle-arresting effects measurable in RNA expression as well as in protein levels and immunocytochemical staining. The combination of citral and capsazepine no longer showed significant pro-apoptotic, antiproliferative, and cell cycle inhibitory effects compared to the compounds alone. This indicates that TRPV1 is necessary for the signal transduction of citral.

Conclusion: This present study reveals three odorant substances with effects on cell viability, indicating their potential use in breast cancer therapy.

Keywords: citral, citrathal R, cyclovertal, odorant substances, olfactory receptor and breast cancer

Introduction
Breast cancer (BC) is the most common type of cancer affecting women and the leading cause of cancer-related deaths among women worldwide.¹ Breast tumors are heterogeneous. According to the World Health Organization (WHO) classification, BC can be categorized by histology.² Depending on the specific molecular subtype, clinical BC management comprises surgery, radiotherapy and chemotherapy.³ Targeted therapy is also increasingly used in specific subtypes.⁴ In addition, a number of integrative therapy options are also available.⁵,⁶ However,
increasing cancer morbidity demands further research and the development of novel therapeutic approaches.

Olfactory receptors (ORs) detect volatile odor molecules in the environment. In 1992, Parmentier et al first detected ORs outside the nose, called ectopic ORs. So far, ORs have already been detected in various ectopic tissues, including breast, colon and liver tissue. The biological functions of ectopic ORs are varied. In particular, they have a regulatory influence on processes, such as sperm chemotaxis, wound healing and cancer cell inhibition. Ectopic ORs are G protein-coupled receptors (GPCRs) activating the Ras/Raf/MAPK pathway and thereby induce specific transcription factors. However, other receptors and transport protein channels, like transient receptor potential channels (TRP) or voltage gated L-type calcium channels, might also be involved in the signal transduction of volatile molecules. TRP channels are well-studied cation channels, which can be activated by a vast number of stimuli. It has also been demonstrated that these cation channels influence cancer growth rates. The odorant substance citral activates TRP channels in dorsal root ganglion cells, raising the question of whether odorant substances might also have effects without activating the olfactory receptors at all. These findings suggest that ORs may be a significant target for future cancer therapy, particularly since G protein-coupled receptors already serve as common therapeutic targets.

In breast tissue, ORs and TRP channels were both expressed and may have an influence on breast carcinogenesis. OR expression differs between healthy and malignant breast tissue. For example, OR2B6 expresses in carcinoma tissue only, qualifying it as a BC biomarker. The study by Masjedi et al suggests that specific OR genes may be correlated with BC characteristics. Therefore, ORs could be potential markers for new diagnostic means and/or therapy. Likewise, TRP channel expression differs between various breast tissues. On the one hand, TRPM8 was not found in healthy breast tissue; on the other hand, TRPV1 and TRPM7 seem to be expressed in any kind of breast tissue. In MCF-7 cells, silencing of TRPM7, the essential TRP channel for calcium homeostasis reduces cell growth. Activation of TRPV1 with the agonist capsaicin can induce anti-proliferative and pro-apoptotic effects. Therefore, TRPV1 has been described as one potential target for cancer therapy.

The present study aims to identify the effect on BC cell growth and viability of the eight odorants para-cymol, citral, hexylacetat, herbavert, dihydromyrcerol, limonen, citral and cyclovertal, which are frequently used in perfumes and cosmetics. The influence was analysed using in vitro BC models. Well-known cellular markers (Table 1) were used to identify the effects of the odorant substances. Ki67 and PCNA (Proliferating Cell Nuclear Antigen) were used as proliferation markers. p53, SIRT1 (sirtuin-1), Survivin and Annexin V were used as markers for apoptosis. The cyclins A2, D1 and E1 and the protein TPX2 (Targeting protein for Xklp2) served as cell cycle markers. Various cellular pathways play an important role in cancer. In order to identify a possibly involved signaling pathway, the signaling pathway markers ERK1/2 (extracellular signal-regulated kinases 1/2), p38 MAPK (p38 mitogen-activated kinase) and STK24 (serine/threonine kinase 24) were used as markers for apoptosis.

### Table 1: Cellular Markers and Their Reported Function

| Cellular Markers | Reported Function | References |
|------------------|------------------|------------|
| Ki 67 | Proliferation marker | [24] |
| PCNA | Various effects on replication, cell cycle and repair mechanisms. | [25] |
| p53 | p53 induces apoptosis by activating pro-apoptotic proteins | [26] |
| SIRT1 (sirtuin-1) | Anti-apoptotic effect by inactivation of p53 | [27] |
| Survivin | Anti-apoptotic by inhibiting caspase-9 and further regulates mitotic spindle checkpoints | [28] |
| Annexin V | Binds the externalised phospholipids on the outer cell membrane during apoptosis | [29] |
| Cyclins A2, D1 and E1 | Activating proteins at cell cycle checkpoints. Elevated levels of cyclin D1 were also shown to increase invasion capability of breast cancer cell lines. | [30] |
| TPX2 (Targeting protein for Xklp2) | Necessary for spindle function and chromosome segregation during mitosis. Its overexpression is associated with tumor growth. | [31] |
| ERK1/2 (extracellular signal-regulated kinases 1/2) | Function in the pro-cancerous and pro-proliferative Ras/Raf-pathway. | [32] |
| p38 MAPK (p38 mitogen-activated kinase) | Associated with Ras/Raf-pathway; transmits mostly inflammatory and apoptotic signals. | [33] |
| STK24 (Serine/threonine kinase 24) | Higher expressions are associated with more aggressive breast cancer subtypes. Associated with the Ras/Raf pathway | [34,35] |
threonine kinase 24) were investigated. Furthermore, this study aimed to understand whether ORs or TRP channels are involved in the potential growth inhibitory effect of the odorant substances in BC cell lines.

**Methods**

**Chemicals**
The tested odorant substances para-cymol (CAS: 99-87-6), citral (CAS: 5392-40-5), heylacetat (CAS: 142-92-7), herbavert (CAS: 67583-77-1), dihydromyrcenol (CAS: 18479-58-8), limonene (CAS: 5989-27-5), citrathal R (CAS: 90480-35-6) and cyclovertal (CAS: 67801-65-4) were provided by Henkel (Henkel Fragrance Center; Krefeld, Germany). Names based on the IUPAC nomenclature are supplemented (Table 2). The substances were diluted into dimethyl sulfoxide (DMSO, Honeywell International Inc., Offenbach, Germany). The TRPV1 inhibitor capsazepine was purchased from Abcam (Cambridge, UK).

**Cell Culture**
BT474 cells (#300131) and T-47D cells (#300353) were purchased from CLS Cell Lines Service GmbH (Eppelheim, Germany), MDA-MB-231 cells (#92020424) from Sigma-Aldrich (Taufkirchen, Germany). Cells were recently (01/2019) authenticated by PCR-single-locus-technology by Eurofins Medigenomix Forensik GmbH (Ebersberg, Germany).

BT474 and MDA-MB-231 were cultivated in Dulbecco’s Modified Eagle Medium with F12 nutrient solution (DMEM/F12, Gibco, Thermo Fisher Scientific, Waltham, USA) containing 5% fetal bovine serum (Gibco), 1% HEPES buffer (Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-Aldrich). T-47D cells were cultivated in Roswell Park Memorial Institute Medium (RPMI, Gibco) containing 5% fetal bovine serum (Gibco), 1% HEPES buffer (Sigma-Aldrich), 1% penicillin/streptomycin (Sigma-Aldrich) and 2.5µL/mL insulin (Sanofi, Frankfurt). All cells were cultured in an incubator with humidified atmosphere (37°C, 5% CO$_2$ and 95% air).

**Substance Application**
For substance application, cells were passaged and grown in 75 cm$^2$ culture flasks. After a confluence of 80% was reached the substance was applied, and cells were incubated for 24 hours in a separate incubator. An equimolar amount of DMSO served as control. For inhibition of TRPV1, the equimolar amount of capsazepine was co-applied with the odorant substance and incubated for further 24 hours in a different incubator.

**RNA-Isolation, cDNA-Synthesis and Polymerase Chain Reaction (PCR)**
Total RNA isolation was performed according to manufacturer’s instructions with TRIzol® Reagent (Thermo Fisher Scientific, Braunschweig, Germany) and chloroform was added to separate the aqueous and organic phase by centrifugation. The aqueous phase contained the RNA, which was further purified using the EURx GeneMatrix UNIVERSAL RNA/miRNA Purification Kit (Roboklon, Berlin, Germany).

Reverse transcription was performed for cDNA synthesis. First, the amount of RNA in each sample was quantified with the NanoPhotometer® N60 (Implen GmbH, Munich, Germany). The Master Mix for reverse transcription contained 5 µL 5x-M-LV-RT-buffer (Thermo Fisher Scientific), 1 µL 5 mM dNTP (Jena Bioscience, Jena, Germany), 1 µL RT-Primer (Jena Bioscience), 0.25 µL Maxima RT (200 U/µL, Thermo Fisher Scientific) and 0.25 µL Superasein (20 U/µL, Invitrogen, Life Technologies, Darmstadt, Germany) for each sample. 2 µg RNA was added per sample. The RT protocol included time-temperature intervals of 1 min 65°C, 30 min 50°C, 10 min 85°C using the Mastercycler nexus gradient (Eppendorf, Wesseling-Berzdorf, Germany). Gene expression was quantified by real-time PCR with a PCR-MasterMix containing 9 µL in-house qPCR Mastermix (containing

| Odorant Substance | IUPAC |
|-------------------|-------|
| Para-cymol (CAS: 99-87-6) | Para-mentha-1,8(9)-dien |
| Citral (CAS: 5392-40-5) | 3,7-dimethylocta-2,6-dienal |
| Hexylacetate (CAS: 142-92-7) | CBH16O2 |
| Herbavert (CAS: 67583-77-1) | 3-ethoxy-1,1,5-trimethylcyclohexane |
| Diodydromyrcenol (CAS: 18479-58-8) | 2,6-dimethylcact-7-en-2-ol |
| Limonene (CAS: 5989-27-5) | 1-methyl-4-prop-1-en-2-ylicyclohexene |
| Citrathal R (CAS: 90480-35-6) | 2,6-Octadienal, 3,7-dimethyl-, acid-isomerized |
| Cyclovertal (CAS: 67801-65-4) | 3,6-dimethylcyclohex-3-ene-1-carbaldehyde |
TRIS pH 8.1, dATP, dCTP, dGTP, dTTP, magnesium, potassium ammonium, SYBR Green (Jena Bioscience, Jena, Germany), enhancers, Hot Start Taq Polymerase (Jena Bioscience) and 1 μL cDNA for each sample. All primer sequences are listed in Table 3. The PCR protocol included preincubation at 95°C, 40 cycles of 60°C–95°C–60°C and a melting curve from 65°C to 95°C using the Light Cycler.

### Table 3 Primer Sequences

| Primer | Sequence |
|--------|----------|
| ALAS1 | S: 5′- AGC GCA ACG TCA AAC TCA T -3′<br>AS: 5′- TTT TAG CAG CAT CTG CAA CAC -3′ |
| Cyclin A2 | S: 5′- CAT GTC AGT GCT GAG AGG AAA -3′<br>AS: 5′- TAC ACA AAC TCT GCT ACT TCT GG -3′ |
| Cyclin D1 | S: 5′- GGG TTG TGC TAC AGA TGA TAG AG -3′<br>AS: 5′- AGA CGC CTC CTT TGT GAT AAT -3′ |
| Cyclin E1 | S: 5′- CCG GGT TTA CCC AAA CTC C -3′<br>AS: 5′- CCA GAC TTC CTC TCT ATT TGC C -3′ |
| ERK1 | S: 5′- TAC ACG CAG TTG CAG TAC AT -3′<br>AS: 5′- CAG TAG GTC TGA TGT TCG AAG G -3′ |
| ERK2 | S: 5′- CTA CAC CAA CCT CTC GTA CAT C -3′<br>AS: 5′- CAG TAG GTC TGA TGT TCG AAG G -3′ |
| ESR B17 (estrogen receptor) | S: 5′- AAG AGG GTG CTC CCA GGC TTT G -3′<br>AS: 5′- TGG GGA ACC GAG ATG ATG TA -3′ |
| GAPDH | S: 5′- GGT GTG AAC CAT GAG AAG TAT GA -3′<br>AS: 5′- GAG TCC TTC CAC GAT ACC AAA G -3′ |
| Ki67 | S: 5′- GAC TTC AAA CTG GCT CCT AAT C -3′<br>AS: 5′- GCC GCC AGA TAG CAG AAA G -3′ |
| p38 MAP/kinase | S: 5′- CAG GAG CTT AAC AAG ACA ATC T -3′<br>AS: 5′- TCT TCA CTT CCA CAC GTA A -3′ |
| p53 | S: 5′- GTC TGG TCT TGC TCT ATT CT -3′<br>AS: 5′- GCA CAG GCC AGG AAC GGC TGG AGT -3′ |
| PGR (progesterone receptor) | S: 5′- CGA GAG GCA ACT TCT TTC AGT A -3′<br>AS: 5′- CCA TCC TAG ACC AAA CAC CAT TA -3′ |
| SIRT1 | S: 5′- CGG ACT CCT AAG CTA GGA TGT T -3′<br>AS: 5′- CAG AGA GAT GGC TGG AAT TGT |
| STK24 | S: 5′- CGT TGG AAG GAA ACT ACA GTA AAC -3′<br>AS: 5′- TGC ATG AGC TCG AGC TGG AAG -3′ |
| Survivin | S: 5′- CGA GGC TGG CTT CAT CCA CT -3′<br>AS: 5′- AGC GCG CAC TCT CGC AGC -3′ |
| TBP | S: 5′- GGT GTA AAG GAC AGA GCA AAA -3′<br>AS: 5′- CAA GGG TAC ATG AGC GCC ATT A -3′ |
| TPX2 | S: 5′- GGC CTT CCT GGT TCT CTA GGT C -3′<br>AS: 5′- CTT CTA CCT CAG CCA TTC TCT TC -3′ |

### MTT-Assay

The MTT-Assay was performed to evaluate the IC50 (quantitative measure that indicates how much of a particular inhibitory substance is needed to inhibit, in vitro, a given biological process or biological component by 50%). The cells were seeded at a density of 40,000/mL (BT474 and MDA-MB-231) and 45,000/mL (T-47D) in 24-well plates. At a confluence of 80%, the medium was replaced by a medium containing substance in concentrations of 25 μM, 50 μM, 75 μM, 100 μM and 150 μM. An equal amount of pure DMSO served as control. After incubating for 24 hours in a separate incubator, 10% MTT (Biomol, Hamburg, Germany, 5mg/mL PBS) was dosed to each well. After two hours, the medium was carefully aspirated and 500 μL lysis buffer (Isopropanol (Sigma-Aldrich), 1% Triton-X (Sigma-Aldrich), 0.1% HCl (32%, Merck, Darmstadt, Germany)) were added to dissolve the formazan crystals. The optical density was measured with the μQuant™ Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, USA) at 570 nm, and the dose–effect curve was calculated.

### Protein Isolation, BCA-Assay and Western Blot

For protein isolation, 350 μL 100% ethanol (Sigma-Aldrich) was added to precipitate DNA first. After pelleting the protein with isopropanol, the protein pellet was washed with 70% ethanol, air-dried and protein lysis buffer (1% SDS (Carl Roth, Karlsruhe, Germany), 1% Triton-X (Sigma-Aldrich), 0.1% HCl (32%, Merck, Darmstadt, Germany)) were added to dissolve the pellet again. To quantify the protein concentration, a BCA-assay was performed with the BCA Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Western Blot technique was performed according to the recommendations of Schagger and von Jagow. The antibodies, namely β-Tubulin (sc-55529, dilution 1:1000), PCNA (sc-56, dilution 1:200), p53 (sc-126, dilution 1:2000), were all purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, USA). ERK1/2 (4695, dilution 1:1000) was purchased from Cell Signaling Technology (Frankfurt, Germany) and TRPV1 (SAB3501027, dilution 1:50 + 3µM L-glutathione reduced) was purchased from Sigma-Aldrich (St. Louis, USA).

After washing, the membranes were incubated for one hour with peroxidase-conjugated goat anti-mouse IgG secondary antibody (for β-Tubulin and PCNA,
buffered formaldehyde (4%, Carl Roth). Antigen retrieval was five hours, followed by a fixation of the cells in a medium containing citral, citrathal R or cyclovertal, at room temperature (20°C). Both antibodies were purchased from Jackson ImmunoResearch Europe Ltd. (Suffolk, UK). β-Tubulin served as loading control. Finally, the immunocomplexes were made visible by ECL according to Haan and Behrmann and exposure to X-ray film (Fujifilm Europe GmbH, Düsseldorf, Germany).

Immunocytochemistry

BT474, T-47D and MDA-MB-231 cells were grown on microscope slides (SuperFrost® Plus, R. Langenbrinck, Emmendingen, Germany) in cell culture plates. At a confluence of 80%, the medium was replaced by a medium containing citral, citrathal R or cyclovertal, each 50 µM. DMSO served as control. Incubation time was five hours, followed by a fixation of the cells in buffered formaldehyde (4%, Carl Roth). Antigen retrieval was performed with 10 mM sodium citrate buffer pH6. PBS containing 0.5% dry non-fat milk (AppliChem GmbH) and 0.5% BSA (AppliChem GmbH) was used as blocking solution. Primary antibody was diluted in blocking solution, and cells were incubated for two hours. The antibodies used Annexin V (sc-32321, dilution 1:250) and PCNA (sc-56, dilution 1:7500) were both purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, USA). After washing, the slides were incubated with ImmPRESS™ HRP reagent peroxidase goat anti-mouse IgG (MP-7452, Vector Laboratories Inc., Burlingame, CA) and Haemalaun acidic Mayer (Waldeck, Münster, Germany). The Axioplan 2 microscope (Zeiss, Oberkochen, Germany) was used to analyse the images.

Statistics

All tests were performed in independent triplicates. Immunocytochemistry was performed as an independent duplicate. qRT-PCR analysis followed the delta–delta CT method described by Livak and Schmittgen calculated in Excel using GAPDH, ALAS1 and TBP as housekeeping genes. All statistical tests were performed in R 4.0.2. The untreated BT474 cell line was defined as the expected control value (intercept). The influence of treatment on RNA expression levels was investigated using a linear model with factor cell line (BT474, T47D, MDA-MB-231) and an interaction term of cell line and treatment (control, citral, citrathal R, cyclovertal, capsazepine, citral + capsazepine, citrathal R + capsazepine, cyclovertal + capsazepine).

Results

The effect of the poly-substance mixture, containing 20 µM of para-cymol, citral, hexylacetat, herbavert, dihydromyrcerol, limonen, citrathal R and cyclovertal, was investigated and results showed that the RNA expression of Ki67 was downregulated in all three cell lines. Consequently, further tests were performed to evaluate which of the eight substances was effective as a single agent. Citral, citrathal R and cyclovertal were revealed to be effective on all three cell lines as they downregulated the Ki67-RNA expression (Supplemental Figure 1). Thus, an MTT-assay was performed for these three specific substances to determine their corresponding IC50 values.

MTT-Assay

The determined dose effect curves are shown in Figure 1. All IC50 values were between 50µM and 75µM, except for cyclovertal on the T-47D cells with 100µM. Thus, it was decided to use a uniform concentration of 50 µM for all odorant substances to treat all cell lines.

Quantitative Expression Analysis in Effective Dosage Application

Proliferation

RNA expression of Ki67 was significantly reduced in T-47D and MDA-MB-231 cells after treatment with either 50 µM citral, citrathal R or cyclovertal. In the BT474 cell line, the effects were not statistically significant (Figure 2). PCNA-expression was significantly reduced after treatment with 50 µM citral in all three cell lines (T-47D: p < 0.001 MDA-MB-231: p < 0.001, BT474: p < 0.001) and following application of 50 µM citrathal R in T-47D cells (p < 0.001).

Apoptosis

p53-RNA expression was significantly higher in T-47D after treatment with 50 µM citral (p < 0.001). Further, RNA expression of the anti-apoptotic survivin shows significant reductions of expression levels in MDA-MB-231 (p < 0.001) and T-47D (p < 0.001) treated with 50 µM citral, T-47D treated with 50 µM citrathal R (p < 0.001) and MDA-MB-231 treated with 50 µM cyclovertal (p <
0.001). In the BT474 cell line, the effects were not statistically significant (Figure 3). There were no significant regulations for the expression of SIRT1-RNA.

Cell Cycle
Most RNA expression regulations were shown for cyclin A2. In T-47D and MDA-MB-231 cell lines, decreased RNA expression levels were observed after treatment with 50µM citral (p < 0.001) (Figure 4). In MDA-MB-231, BT474 and T-47D cells, cyclin A2 expression was also substantially reduced after treatment with 50 µM citral R (T-47D: p < 0.001, MDA-MB-231: p = 0.004, BT474: p = 0.04). 50 µM cyclovertal reduced cyclin A2 expression notably in MDA-MB-231 cells.
only (p < 0.001). Cyclin D1 expression was reduced in all three cell lines after treatment with 50 µM citral (T-47D: p < 0.001, MDA-MB-231: p = 0.047, BT474: p = 0.017). RNA expression of cyclin E1 also shows a reduction in MDA-MB-231 cells after treatment with 50µM citral (Cit), 50µM citrathal R (CR) and 50µM Cyclovertal (Cy). CTRL: DMSO-Control.

Figure 2 Ki67 in T-47D, MDA-MB-231 and BT474 cells. Relative intracellular expression of Ki67 RNA in T-47D cells (A), MDA-MB-231 cells (B) and BT474 cells (C) after treatment with 50µM citral (Cit), 50µM citrathal R (CR) and 50µM Cyclovertal (Cy). CTRL: DMSO-Control.

Figure 3 Survivin in T-47D, MDA-MB-231 and BT474 cells. Relative intracellular expression of survivin RNA in T-47D cells (A), MDA-MB-231 cells (B) and BT474 cells (C) after treatment with 50µM citral (Cit), 50µM citrathal R (CR) and 50µM Cyclovertal (Cy). CTRL: DMSO-Control.
Moreover, the spindle assembly factor TPX2 showed significant reductions of RNA expression in all investigated cell lines after treatment with 50µM citral (T-47D: \( p < 0.001 \), MDA-MB-231: \( p < 0.001 \), BT474: \( p = 0.035 \)), in T-47D cells after treatment with 50µM citrathal R (\( p < 0.001 \)) and in MDA-MB-231 (\( p = 0.001 \)) and T-47D (\( p = 0.002 \)) cells after treatment with 50 µM cyclovertal.

**Pathways**

ERK1, ERK2, p38-MAPK and STK24 were investigated to elucidate the possible impact of pathway regulations on RNA expression values. Significant reductions in RNA expression of ERK1 in MDA-MB-231 (\( p = 0.034 \)) and T-47D (\( p = 0.020 \)) cells were observed following treatment with 50 µM citral and in BT474 cells after treatment with 50 µM citral R (\( p < 0.001 \)) and in MDA-MB-231 (\( p = 0.001 \)) and T-47D (\( p = 0.002 \)) cells after treatment with 50 µM cyclovertal.

Hormone Receptors

RNA expression of progesterone and estrogen receptors were investigated in the hormone receptor-positive cell lines BT474 and T-47D. 50 µM citral induced a significant reduction of progesterone receptor RNA expression in both cell lines (T-47D: \( p < 0.001 \), BT474: \( p = 0.017 \)), in T-47D also 50 µM citrathal R (\( p < 0.001 \)). RNA expression of estrogen receptors in T-47D cells was significantly reduced after treatment with 50 µM citral (\( p < 0.001 \)) (Supplemental Figure 3).

**Co-Application of Capsazepine and Odorant Substances**

To investigate the role of TRPV1 in the functional processes of the analyzed odorant substances, capsazepine, a TRPV1 inhibitor, was co-applicated simultaneously with 50µM citral, citratal R and cyclovertal, respectively. Capsazepine itself turned out to be a highly potent toxic substance, which significantly reduced both proliferation (Ki67 \( p < 0.001 \) and PCNA \( p < 0.001 \) RNA expression) and survivin (\( p < 0.001 \)) RNA expression levels in all cell lines. Furthermore, the application of capsazepine alone resulted in reduced RNA expressions of cyclins, particularly for the RNA expressions of cyclin D1, which were reduced in all three cell lines (T-47D: \( p = 0.002 \), BT474 and MDA-MB-231: \( p < 0.001 \)).

Due to the analyses revealing that capsazepine itself is a potent substance, we investigated the tumor-suppressive effects of capsazepine plus odorant compared to capsazepine alone. Ki67 expression was significantly reduced in
MDA-MB-231 when capsazepine was combined with
citrathal R (p = 0.019) or cyclovertal (p = 0.022) was
compared to capsazepine alone. The RNA expression of
PCNA in MDA-MB-231 was significantly higher after
treatment with a combination of citral and capsazepine
than after capsazepine treatment alone (p = 0.045)
(Figure 5A). The level of the anti-apoptotic survivin also
increased significantly after treatment with the combina-
tion of citral and capsazepine compared to capsazepine
alone in MDA-MB-231 cells (p = 0.003) (Figure 5B).
Finally, the expression of cyclin A2 and cyclin D1 was
significantly elevated with the combined treatment of citral
and capsazepine compared to capsazepine-treatment alone
in MDA-MB-231 cells (p = 0.024 and p = 0.014)
(Figure 5C and D).

In T-47D cells, the combination of any of the three
odorant substances with capsazepine resulted in
a significant reduction of p53 RNA expression compared
to capsazepine alone (citral p = 0.018, citrathal R p =
0.017, cyclovertal p = 0.006).

In BT474 cells, the cyclin A2 RNA expression was
significantly reduced after co-application of both citrathal
R and capsazepine (p = 0.009) and cyclovertal and capsa-
zapine (p = 0.022), compared to capsazepine alone. Cyclin
D1 RNA expression was significantly higher after co-
applying with the combination of cyclovertal and capsa-
zepine (p = 0.043) compared to capsazepine alone. Finally,
TPX2 RNA expression was significantly reduced after
treatment with citrathal R and capsazepine compared to
capsazepine alone (p = 0.029).

Western Blot

Western blots were performed to investigate alterations in
protein levels after treatment with 50 µM of each of the
odorant substances, citral, citrathal R and cyclovertal alone
and in combination with 50 µM capsazepine.

PCNA was investigated for the proliferation rate and
p53 for level of apoptosis. Further, TRPV1 expression was
measured to determine the influence of capsazepine itself
and the combinations of capsazepine with each of the
odorant substances.

In T-47D cells, PCNA expression was reduced after
the application of capsazepine and the odorant substances
separately. The applications of citral or citral plus capsa-
zepine were equally effective in reducing the PCNA
expression. Citrathal R and cyclovertal, however,
resulted in a higher efficacy in combination with capsa-
zepine than they did individually. All approaches of
T-47D showed an increased expression of p53 when the
odorant substances were applied individually without

Figure 5 Effects of capsazepine. Relative intracellular expression of (A) PCNA, (B) survivin, (C) cyclin A2 and (D) cyclin D1 RNA in MDA-MB-231 cells after treatment with 50µM capsazepine alone (CZ), 50µM citral + 50µM capsazepine (Cit+CZ), 50µM citrathal R + 50µM capsazepine (CR+CZ) and 50µM cyclovertal + 50µM capsazepine (Cy+CZ).
capsazepine compared to the combined treatment. TRPV1 was no longer detectable after the application of capsazepine. These results for p53 and TRPV1 in T-47D were similar to the results in BT474 cells. The PCNA expression in BT474 was also reduced after the application of capsazepine and the odorant substances separately and showed no difference between citral alone and citral plus capsazepine. However, the reduction was more pronounced after concomitant use of citrathal R plus capsazepine and cyclovertal plus capsazepine compared to capsazepine alone. Although PCNA expression reduction occurred due to citral, citrathal R and cyclovertal treatment in MDA-MB-231 cells, capsazepine alone did not reduce PCNA expression, and the combination of citral and capsazepine led to no reduction of PCNA expression. Other in vitro models displayed a different effect. TRPV1 could be detected in all approaches except for the combination of citral and capsazepine. Figure 6 shows the results of the corresponding Western blots.

ERK1 and 2 were used as pathway markers, solely investigated after treatment with 50µM odorant substance and not following combined treatment with capsazepine. ERK1/2 expression was detected with reduced levels triggered by treatment with 50µM citral in T-47D cells and likewise with 50µM citrathal R in T-47D and MDA-MB-231 cells.

Discussion
This study aims at investigating the potential effects of eight commonly used odorant substances (para-cymol, citral, hexylacetat, herbavert, dihydromyrcerol, limonen, citrathal R and cyclovertal) on the growth and vitality of three BC in vitro models: T474, T-47D, MDA-MB-231. Citral, citrathal R and cyclovertal showed anti-proliferative effects.

As previous research described, citral appears to exert anti-proliferative and pro-apoptotic effects, and subsequently induces cell cycle arrest.41–43 The results of the present study confirm these previous findings on BC cell lines and the effects could be verified on RNA- (qRT-PCR) and protein level (Western blot, immunocytochemistry). The IC50 value of citral was 50µM for all cell lines investigated. This value corresponds to quantitative data of previous approaches.43,44 Chaouki et al investigated the effect of citral on apoptosis with an LDH-assay and concluded that concentrations of 200µM and lower lead rather to specific apoptotic effects than to necrosis or cell lysis.42 In the present study, the concentration of 50µM, which was determined by the MTT assay, also led to changes in

![Figure 6](https://doi.org/10.2147/BCTT.S322619) Western blots. Western Blot showing control, capsazepine alone, citral, citral + capsazepine, citrathal R, citrathal R + capsazepine, cyclovertal and cyclovertal + capsazepine. ß-tubulin served as loading control in (A) T-47D, (B) BT474, (C) MDA-MB-231.
Figure 7  Immunocytochemistry. 1: T-47D PCNA. Immunocytochemical staining of T47D cells with PCNA antibody (dilution 1:7500, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Compared to control reduced nuclear–cytoplasmic ratio and increased nuclear condensation. 2: T-47D Annexin V. Immunocytochemical staining of T47D cells with Annexin V antibody (dilution 1:250, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Compared to control reduced nuclear–cytoplasmic ratio and increased nuclear condensation. Slightly increased staining of the outer cell membrane after citral treatment, more after citrathal R and cyclovertal, compared to the control. 3: BT474 PCNA. Immunocytochemical staining of BT474 cells with PCNA antibody (dilution 1:7500, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Compared to control reduced nuclear–cytoplasmic ratio and increased nuclear condensation. 4: BT474 Annexin V. Immunocytochemical staining of BT474 cells with Annexin V antibody (dilution 1:250, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Clearly increased staining of the outer cell membrane after citral, cylovertal and mostly after citrathal R treatment compared to the control. 5: MDA-MB-231 PCNA. Immunocytochemical staining of MDA-MB-231 cells with PCNA antibody (dilution 1:7500, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Compared to control reduced condensation and increased fragmentation of the nucleus and loss of spindle-shape after treatment mostly with citral and citrathal R, but also cyclovertal. Less intensive staining of the nuclei after treatment with citral, citrathal R and cyclovertal compared to the control. 6: MDA-MB-231 Annexin V. Immunocytochemical staining of MDA-MB-231 cells with Annexin V antibody (dilution 1:250, microscopic enlargement 400x). (a) control, (b) citral, (c) citrathal R, (d) cyclovertal. Compared to control reduced condensation and increased fragmentation of the nucleus and loss of spindle-shape after treatment with citral, citrathal R and cyclovertal. Increased staining of the outer cell membrane after citral, citrathal R and mostly after cyclovertal treatment compared to the control.
various apoptosis markers (Figures 3 and 4). Concerning apoptosis, Dudai et al reported the induction of caspase 3, a pro-apoptotic enzyme, by citral which also suggests the effect to be mediated by specific targets.\textsuperscript{45} Cell cycle arrests were described in G2/M and G0/G1.\textsuperscript{42,43} The downregulation of cyclin A2, D1 and E1 shown in this study indicates cell cycle arrests in G1 (cyclin D1), G1/S (cyclin E1) and S (cyclin A2).\textsuperscript{30,46,47} This emphasizes its potential role in BC therapy.

Similar anti-proliferative and pro-apoptotic effects were demonstrated for the odorant substances citrathal R and cyclovertal. No scientific literature is currently available regarding these substances and their anti-proliferative and pro-apoptotic effects, and thus it is recommended they are introduced as new potent substances for growth inhibition in BC cell lines due to their demonstrated therapeutic potential. Since citrathal R is described to be the reaction product of citral and ethanol in the manufacturers’ data sheet and consequently has structural similarity with citral, it can be assumed that their mode of action is similar. However, in the present study, the anti-proliferative effect of citral on BC cells appears to be TRPV1-mediated. Citrathal R additionally shows a TRPV1-independent effect. This TRPV1-independent effect could also be shown for cyclovertal.

Further studies are needed to investigate the potential therapeutic effects of citrathal R and cyclovertal.

As mentioned in the introduction, the literature suggests that odorant substances transfer their effects via olfactory receptors, which are classified as G-protein coupled receptors.\textsuperscript{12} They bind to the receptors, activate them and transduce signals by activating different MAP kinases like ERK1, ERK2 and p38-MAPK. In this study, certain changes in the RNA expression levels were seen for ERK1/2 and p38-MAPK as described in the results. This indicates pathway regulations after treatment with odorant substances, but further studies are necessary for precise statements.

The determination of the relevant ectopic OR would be useful here. For this purpose, experiments with a knockout of the eligible receptors would be possible. In previous studies, the effect of citral on TRPV1 and other TRP channels has been shown.\textsuperscript{17,46} Based on this information, this study aimed to investigate the role of TRPV1 in the mechanisms of action of citral, citrathal R and cyclovertal. Beyond expectations, the TRPV1 inhibitor capsazepine, used in the experiments, showed an anti-proliferative and pro-apoptotic effect itself.\textsuperscript{49,50} Weber et al investigated the expression and functionality of TRPV1 in the triple-negative BC cell line SUM149PT. As in the current study, they applied a concentration of 50µM capsazepine. However, Weber et al did not describe an anti-proliferative and pro-apoptotic effect.\textsuperscript{23} Fazzari et al tested capsazepine on MDA-MB-231 cells and showed evidence for a reduction in cell viability after application of 50µM capsazepine, similar to the findings by Vercelli et al in MCF-7 BC cells.\textsuperscript{49,50} This could imply that the effect of capsazepine might be different between various cell lines. The present study demonstrated an anti-proliferative and pro-apoptotic effect of capsazepine on MDA-MB-231, T-47D and BT474 cells. The important role of TRP channels in cell calcium homeostasis, which itself is important for cell viability, could account for this effect.\textsuperscript{22} However, this study concluded that the combined application of capsazepine and odorant substance compared to capsazepine alone showed only limited regulations. Nonetheless, in MDA-MB-231 cells, we identified a significantly higher proliferation (elevated PCNA RNA expression), reduced apoptosis (elevated survivin RNA expression) and elevated cyclin A2 and D2 RNA expression levels following treatment with a combination of citral and capsazepine compared to capsazepine alone. This could be substantiated by the results on protein level by an elevated expression of the PCNA protein after combined treatment with citral and capsazepine compared to capsazepine treatment alone. The increased proliferation suggests that TRPV1 is essential for signal transduction in the mechanisms of action of citral. In T-47D, combinations of any of the three odorant substances with capsazepine resulted in lower p53 RNA expression levels than capsazepine alone, which indicates less apoptosis when inhibiting the TRPV1 channel. In contrast, in BT474 citrathal R and cyclovertal effect mechanisms are triggered and work, even though TRPV1 is inhibited. Ultimately, these data suggest that the signalling cascade connected to TRPV1 is needed for treatment with citral. No effects could be observed without TRPV1. For citrathal R and cyclovertal TRPV1 might play a signalling role. Still, effects are measurable in BT474 when inhibiting TRPV1. There might also be a difference among various cell lines, depending on their expression patterns.

Moreover, the data of the present study showed a reduced expression of estrogen and progesterone receptor RNA. This could result in reduced hormone receptor expression on the cell surface (Supplemental Figure 3). This might play an important role in successful BC
therapy, as the estrogen receptors are one of the most important therapy targets. Reduced expression of these receptors might cause therapy failure of the endocrine treatment, like tamoxifen, for instance.41 The reduction in expression could also be potentially used therapeutically. The application of odorants shows an antiproliferative effect. In combination with the expression reduction of the hormone receptors, the effect could also be similar to SERD, such as fulvestrant. Additional studies are necessary to determine whether fragrances might also cause a reduction in the expression of estrogen receptors in vivo.

The exact mode of action of citral, as well as of citrathal R and cyclovertal, is not yet fully understood. There are descriptions of certain molecular effects, eg p53 induction and modulation of oxidative stress, as well as their effects on ALDH1A3 and ALDH in the context of drug resistance.41,44,52 However, none of them contains complete information about the mechanisms by which these effects are transduced from the cell surface.

Since the odorous substances bind to ORs, it is obvious that ectopic ORs are involved in signal transduction. The results of the current study suggest that the effect of citral is partly mediated by the TRPV1 receptor. Masjedi et al showed that the expression of different ectopic ORs varies in different BC cell lines. They suggested that the different expression of the ORs is related to the cell lines of the BC subtypes.20 The different endowment of ectopic ORs of BC subtypes could have a potential biomarker function and might have therapeutic potential, too. The three fragrances investigated showed a therapeutically interesting effect. It is possible that there are other substances in the field of fragrances with similar or better therapeutically useful effects. Future studies will have to show whether the associated possible therapeutic potential of fragrances can be used. The mode of application, in the form of solutions and creams, is also still unclear.

As this study is limited to in-vitro investigations, equivalent in-vivo effects of the odorant substances can only be assumed. In particular, questions like the possibility of odorant application and the achievement of sufficient doses of breast tissue in vivo have not yet been answered.

Conclusion
This study shows that the odorant substances citral, citrathal R and cyclovertal have anti-proliferative, pro-apoptotic and cell cycle arresting effects on the three BC cell lines T-47D, BT474 and MDA-MB-231. This effect offers a potential therapeutic option for the future therapy of BC. Moreover, an effect on the expression of hormone receptor RNA expression levels was shown, which might represent an interesting target for re-adjustment following unsuccessful therapy. Finally, this study suggests that TRPV1 is a critical component of an effective citral-based treatment to evolve its antiproliferative effect on BC cells. For citrathal R and cyclovertal signaling, TRPV1 might play a functional role; however, the crucial mechanism seems to work independently of TRPV1 and has not yet been described. Further studies are required to identify and qualify this mechanism and the in vivo effect of the odorant substances.

Abbreviations
BC, breast cancer; ERK1/2, extracellular signal-regulated kinases ½; GPCRs, G protein-coupled receptors; ORs, Olfactory receptors; p38 MAPK, p38 mitogen-activated kinase; PCNA, Proliferating Cell Nuclear Antigen; RNA, ribonucleic acid; STK24, serine/threonine kinase 24; TPX2, targeting protein for Xklp2; TRP, transient receptor potential channels; WHO, World Health Organization.

Data Sharing Statement
The datasets analysed during the current study are available from the corresponding authors on reasonable request.

Acknowledgments
We express our special thanks to Mrs. Claudia Nothling for her excellent work as a medical-technical assistant.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492

2. Lakhani SR; International Agency for Research on Cancer, Weltgesundheitsorganisation, editors. WHO Classification of Tumours of the Breast: Views of a Working Group That Convened for a Consensus and Editorial Meeting at the International Agency for Research on Cancer (IARC), Lyon, September 1–3, 2011. 4ed. Internat. Agency for Research on Cancer; 2012.

3. Harbeck N, Gniant M. Breast cancer. Lancet Lond Engl. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8

4. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–244. doi:10.1016/S1470-2241(11)70033-X

5. Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232. doi:10.3322/caac.21492

6. Lopes CM, Dourado A, Oliveira R. Phytotherapy and nutritional supplements on breast cancer. BioMed Res Int. 2017;2017:1–42. doi:10.1155/2017/7207983

7. Parmentier M, Libert F, Schurmans S, et al. Expression of members of the putative olfactory receptor gene family in mammalian germ cells. Nature. 1992;355(6359):453–455. doi:10.1038/355453a0

8. Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS One. 2013;8(2):e55368. doi:10.1371/journal.pone.0055368

9. Spehr M, Gisselmann G, Poplawski A. Identification of a testicular odorant receptor mediating human sperm chemotaxis. Science. 2003;299(5561):2054–2058. doi:10.1126/science.1080376

10. Busse D, Kudella P, Grünning N-M, et al. A synthetic sandalwood odorant induces wound-healing processes in human keratinocytes via the olfactory receptor OR2AT4. J Invest Dermatol. 2014;134(11):2823–2832. doi:10.1038/jid.2014.273

11. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem. 2009;284(24):16218–16225. doi:10.1074/jbc.M109.012096

12. Maßberg D, Hatt H. Human olfactory receptors: novel cellular functions. Transd Knowl Environ. 2015;4ed. doi:10.1152/tkde.2007.11734517

13. Spehr J, Gelis L, Osterloh S, Brauhoff P, et al. Functional characterization of the odorant receptor 51E2 in human melanocytes. J Biol Chem. 2016;291(34):17772–17786. doi:10.1074/jbc.M116.734517

14. Manteniotis S, Wojciek S, Brauhoff P, et al. Functional characterization of the ectopically expressed olfactory receptor 2A4 in human myelogenous leukemia. Cell Death Discov. 2016;2(1). doi:10.1038/cddiscovery.2015.70

15. Montell C. The TRP superfamily of cation channels. Sci STKE Signal Transduct Knowl Environ. 2005;2005(272):re3. doi:10.1126/stke.27205rese3

16. Stotz SC, Vriens J, Martyn D, Clardy J, Clapham DE. Citral sensing by TRANSsient receptor potential channels in Dorsal Root Ganglion neurons. PLoS One. 2008;3(5):e2082. doi:10.1371/journal.pone.0002082

17. Liebmann C. G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des. 2004;10(16):1937–1958. doi:10.2174/1381612043483467

18. Weber L, Maßberg D, Becker C, et al. Olfactory receptors as bio-markers in human breast carcinoma tissues. Front Oncol. 2018;8. doi:10.3389/fonc.2018.00033

19. Masjedi S, Zwiebel LJ, Giorgio TD. Olfactory receptor gene abundance in invasive breast carcinoma. Sci Rep. 2019;9(1):13736. doi:10.1038/s41598-019-50085-4

20. Dheninn-Duthille I, Gautier M, Faouzi M, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011;28(5):813–822. doi:10.1006/jjpic.2002.10062.002

21. Weber LV, AL-Refai K, Wölk G, et al. Expression and functionality of TRPV1 in breast cancer cells. Breast Cancer Targets Ther. 2016;8:243–252. doi:10.2147/BTCTTT.S121610

22. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–322. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9

23. Jurkóvá M, Danihel L, Polák Š, Varga I, Kíč, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2011;68(5):544–552. doi:10.1016/j.acthis.2016.05.002

24. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458(7242):1127–1130. doi:10.1038/nature07986

25. Vaziri H, Desaii SK, Ng Eaton E, et al. hSir2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149–159. doi:10.1016/S0092-8674(01)00527-x

26. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000–5005. doi:10.1158/1078-0432.CCR-07-08476

27. Brumatti G, Sheridan C, Martin SJ. Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells. Methods. 2008;44(3):235–240. doi:10.1016/j.ymeth.2007.11.010

28. Zhong Z, Yeow W-S, Zou C, et al. Cyclin D1/Cyclin-dependent Kinase 4 interacts with Filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010;70(5):2105–2114. doi:10.1158/0008-5472.CAN-09-1108

29. Aguirre-Portoles C, Bird AW, Hyman A, Canamero M, Perez de Castro M, Malumbres M. Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012;72(6):158–1528. doi:10.1158/0008-5472.CAN-11-1971

30. Smith C, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta BBa Mol Cell Res. 2007;1773(8):1263–1284. doi:10.1016/j.bbamcr.2006.10.001

31. Cuesta A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochem Biophys Acta BBa Mol Cell Res. 2007;1773(8):1358–1375. doi:10.1016/j.bbamcr.2007.03.010

32. O’Neill E, Rushworth L, Baccarini M, Koleh W. Role of the Kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science. 2004;306(5705):2267–2270. doi:10.1126/science.1103233
35. Madsen CD, Hooper S, Tozlouglu M, et al. STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol. 2014;17(1):68–80. doi:10.1038/ncb3083
36. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166(2):368–379. doi:10.1016/0003-2697(87)90587-2
37. Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007;318(1–2):11–19. doi:10.1016/jijim.2006.07.027
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods San Diego Calif. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
39. Microsoft Corporation. Microsoft Excel; 2017.
40. R Foundation for Statistical Computing. R Core Team. R: a language and environment for statistical computing; 2020. Available from: https://www.R-project.org/. Accessed November 9, 2020.
41. Nigjeh SE, Yeap SK, Nordin N, Kamalideghan B, Ky H, Rosli R. Citral inhibits cell proliferation and induces apoptosis in MDA-MB-231 spheroid cells. BMC Complement Altern Med. 2018;18(1). doi:10.1186/s12906-018-2115-y
42. Chaouki W, Leger DY, Liagre B, Beneytout J-L, Hmamouchi M. Citral induced apoptosis in MCF-7 cells. J Breast Cancer. 2015;18(3):225. doi:10.4048/jbc.2015.18.3.225
43. Patel PB, Thakkar VR, Patel JS. Cellular effect of curcumin and citral sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166(2):368–379. doi:10.1016/0003-2697(87)90587-2
44. Kapur A, Felder M, Fass L, et al. Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation. Sci Rep. 2016;6(1). doi:10.1038/srep27530
45. Dudai N, Weinstein Y, Krup M, Rabinski T, Ofir R. Citral is a new inducer of Caspase-3 in tumor cell lines. Planta Med. 2005;71(5):484–488. doi:10.1055/s-2005-864146
46. Sauer K, Lehner CF. The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res. 1995;1:125–139
47. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992;11(3):961–971. doi:10.1002/j.1460-2075.1992.tb05135.x
48. Ohtsubo S, Fujita T, Matsuhashita A, Kumamoto E. Inhibition of the compound action potentials of frog sciatic nerves by aroma oil compounds having various chemical structures. Pharmacol Res Perspect. 2015;3(2):e00127. doi:10.1002/prp2.127
49. Fazzari J, Lin H, Murphy C, Ungard R, Singh G. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015;5(1). doi:10.1038/srep08380
50. Vercelli C, Barbero R, Cuniberti B, et al. Transient receptor potential vanilloid 1 expression and functionality in MCF-7 cells: a preliminary investigation. J Breast Cancer. 2014;17(4):332. doi:10.4048/jbc.2014.17.4.332
51. Haque M, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol. 2019;10. doi:10.3389/fendo.2019.00573
52. Thomas ML, de Antueno R, Coyle KM, et al. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3. Mol Oncol. 2016;10(9):1485–1496. doi:10.1016/j.molonc.2016.08.004

Breast Cancer: Targets and Therapy

Publish your work in this journal

Breast Cancer - Targets and Therapy is an international, peer-reviewed open access journal focusing on breast cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/breast-cancer--targets-and-therapy-journal

Dovepress

Breast Cancer: Targets and Therapy 2021:13